Enhanced bimatoprost ophthalmic solution

Abstract

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

What is claimed is: 
     
         1 . A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration. 
     
     
         2 . The composition of  claim 1  which further comprises an effective amount of EDTA. 
     
     
         3 . The composition of  claim 2  wherein the concentration of benzalkonium chloride is from 150 ppm to 200 ppm. 
     
     
         4 . The composition of  claim 3  having a pH of 7.4 which consists essentially of 0.0125% bimatoprost, 200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer, NaCl, and water. 
     
     
         5 . The composition of  claim 1  wherein the concentration of bimatoprost is from 0.005% w/v to 0.015% w/v. 
     
     
         6 . The composition of  claim 5  wherein the concentration of bimatoprost is from 0.0125% w/v to 0.015% w/v. 
     
     
         7 . The composition of  claim 6  wherein the concentration of benzalkonium chloride is from 100 ppm to 150 ppm. 
     
     
         8 . The composition of  claim 7  wherein the concentration of benzalkonium chloride is 100 ppm. 
     
     
         9 . The composition of  claim 6  which further comprises an effective amount of EDTA. 
     
     
         10 . The composition of  claim 9  having a pH of 7.4 which comprises 0.015% bimatoprost, 200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer, and NaCl. 
     
     
         11 . The composition of  claim 10  having a pH of 7.4 which consists of 0.015% bimatoprost, 200 ppm benzalkonium chloride, from 0 to 0.03% EDTA, a phosphate buffer, NaCl, and water. 
     
     
         12 . A method comprising administering to a mammal suffering from glaucoma or intraocular hypertension a composition comprising from 0.005% to 0.125% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride. 
     
     
         13 . The composition of  claim 12  comprising from 0.001% to 0.15% EDTA. 
     
     
         14 . The composition of  claim 13  comprising from 0.01% to 0.1% EDTA. 
     
     
         15 . The composition of  claim 14  comprising from 0.01% to 0.05% EDTA. 
     
     
         16 . The composition of  claim 12  comprising from 150 to 250 ppm BAK. 
     
     
         17 . The composition of  claim 12  comprising 0.0125% bimatprost.